The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk

被引:107
|
作者
Anderson, JB
Roehrborn, CG
Schalken, JA
Emberton, M
机构
[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[2] Univ Texas, SW Med Ctr, Dallas, TX USA
[3] Univ Nijmegen Hosp, Dept Urol, NL-6500 HB Nijmegen, Netherlands
[4] UCL, Inst Urol & Nephrol, London, England
关键词
benign prostatic hyperplasia; progression; dihydrotestosterone; 5 alpha-reductase inhibitors;
D O I
10.1159/000052475
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute urinary retention, may ensue. Evidence is emerging from long-term clinical studies to suggest that BPH is a progressive disease, with some patients progressing much more rapidly than others. Objective: This article aims to explore the natural history of BPH progression from a molecular, pathological and clinical perspective, with emphasis on the key clinical evidence to support the progressive nature of this disease. How our increased understanding of the disease and of the risk factors for BPH progression might be applied to improve current management practices are also discussed. Conclusion: Strategies to identify patients most at risk and guidelines directed towards longterm management, in addition to short-term treatment, may be useful in helping to prevent BPH progression. Copyright (C) 2007 S. Karger AG. Basel.
引用
收藏
页码:390 / 398
页数:9
相关论文
共 50 条
  • [21] Could inflammation be a key component in the progression of benign prostatic hyperplasia?
    Kramer, G
    Marberger, M
    CURRENT OPINION IN UROLOGY, 2006, 16 (01) : 25 - 29
  • [22] Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia
    Burke, James P.
    Rhodes, Thomas
    Jacobson, Debra J.
    McGree, Michaela E.
    Roberts, Rosebud O.
    Girman, Cynthia J.
    Lieber, Michael M.
    Jacobsen, Steven J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 164 (01) : 41 - 46
  • [23] Evidence based drug therapy of the benign prostatic hyperplasia
    Robert, JP
    Díaz, DC
    REVISTA CLINICA ESPANOLA, 1999, 199 : 48 - 57
  • [24] Benign prostatic hyperplasia and evidence based medicine -: Presentation
    Díaz, DC
    REVISTA CLINICA ESPANOLA, 1999, 199 : 1 - 1
  • [25] Surgical management of benign prostatic hyperplasia: current evidence
    Abdulaziz Baazeem
    Mostafa M Elhilali
    Nature Clinical Practice Urology, 2008, 5 : 540 - 549
  • [26] Extracts from "Clinical Evidence" - Benign prostatic hyperplasia
    Barry, MJ
    Roehrborn, CG
    BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7320): : 1042 - 1046
  • [27] Surgical management of benign prostatic hyperplasia: current evidence
    Baazeem, Abdulaziz
    Elhilali, Mostafa M.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (10): : 540 - 549
  • [28] The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia.
    Kim E.D.
    Current Urology Reports, 2004, 5 (4) : 267 - 273
  • [29] Benign prostatic hyperplasia
    Clarke, HS
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 314 (04): : 239 - 244
  • [30] Benign prostatic hyperplasia
    Wilson, T
    BRITISH JOURNAL OF GENERAL PRACTICE, 1997, 47 (419): : 401 - 401